

# Global associations between air pollutants and Chronic Obstructive Pulmonary Disease hospitalizations: a systematic review

Running head: Air pollution and COPD hospitalizations

## Corresponding author:

Elizabeth Moore, Imperial College London.

National Heart and Lung Institute, Emmanuel Kaye Building, 1B Manresa Road, London,  
SW3 6LR

E: [liz.moore@imperial.ac.uk](mailto:liz.moore@imperial.ac.uk) T: 0207 594 8824

## Authors:

Elizabeth Moore, MSc, Department of Respiratory Epidemiology Occupational Medicine and Public Health, Imperial College London, London, UK <sup>a</sup>

Dr Lia Chatzidiakou, PhD, Department of Chemistry, University of Cambridge, Cambridge, UK<sup>b</sup> T: 01223 336 345

Moyosore-Oluwa Kuku, BSc, Division of Medicine, University College London, London, UK<sup>c</sup> T: 07958 127 256

Professor Roderic L. Jones, DPhil, Department of Chemistry, University of Cambridge, Cambridge, UK<sup>b</sup> T: 01223 336 466

Professor Liam Smeeth, FRCGP, Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK<sup>d</sup> T: 0207 927 2296

Dr Sean Beevers, PhD, Analytical & Environmental Sciences Division, King's College London, London, UK<sup>e</sup> T: 020 7848 4009

Professor Frank J. Kelly, PhD, NIHR Health Protection Research Unit in Heath Impacts of Environmental Hazards, King's College London, London, UK<sup>e</sup> T: 020 7848 4004

Dr Benjamin Barratt, PhD, Analytical & Environmental Sciences Division, King's College  
London, London, UK<sup>e</sup> T: 020 7848 4034

Dr Jennifer Quint, FRCP, PhD, Department of Respiratory Epidemiology Occupational  
Medicine and Public Health, Imperial College London, London, UK<sup>a</sup> T: 020 7594 8821

<sup>a</sup> National Heart and Lung Institute, Emmanuel Kaye Building, 1B Manresa Road, London,  
SW3 6LR

<sup>b</sup> Centre for Atmospheric Science, Department of Chemistry, University of Cambridge,  
Lensfield Road, Cambridge, CB2 IEW

<sup>d</sup> Division of Medicine, University College London, Gower Street, London, WC1E 6BT

<sup>e</sup> Analytical & Environmental Sciences Division, Franklin-Wilkins Building, 150 Stamford  
Street, London, SE1 9NH

Descriptor number: 9.7

MeSH Headings: Patient admission, Particulate matter, Gases, Environmental monitoring

Word count (excluding title page, abstract, figures, and references): 4,348

## Abstract

**Background:** Exacerbations are key events in Chronic Obstructive Pulmonary Disease (COPD), affecting lung function decline and quality of life. The effect of exposure to different air pollutants on COPD exacerbations is not clear.

**Objective:** To carry out a systematic review examining associations between air pollutants and hospital admissions for COPD exacerbations.

**Data sources:** MEDLINE, EMBASE, BIOSIS & Science Citation Index, and the Air Pollution Epidemiology Database were searched from 1980 until September 2015.

**Data extraction:** Inclusion criteria focused on studies presenting solely a COPD outcome defined by hospital admissions, and a measure of gaseous air pollutants and particle fractions. The association between each pollutant with COPD admissions was investigated in meta-analyses using random-effects models. Analyses were stratified by geographical clusters to investigate the consistency of the evidence worldwide.

**Synthesis:** 46 studies were included and results for all the pollutants under investigation showed marginal positive associations; however the number of included studies was small with high heterogeneity between them and there was evidence of small-study bias. Geographical clustering of the effects of pollution on COPD hospital admissions was evident and reduced heterogeneity significantly.

**Conclusions:** The most consistent associations was between a  $1\text{mg}/\text{m}^3$  increase in carbon monoxide levels with COPD related admissions; Odds Ratio: 1.02 (95%CI: 1.01-1.03). The heterogeneity was moderate and there was a consistent positive association in both Europe and North America, although levels were clearly below WHO guideline values.

There is mixed evidence on the effects of environmental pollution on COPD exacerbations.

Limitations of previous studies included the low spatio-temporal resolution of pollutants,

inadequate control for confounding factors, and the use of aggregated health data that ignore personal characteristics. The need for more targeted exposure estimates in a large number of geographical locations is evident.

**Funding:** This research was funded by the Medical Research Council (MR/L019744/1).

Word count: 297

## **Introduction**

Intense energy consumption together with industrial and transportation emissions, have led to population exposure to a diverse variety of unhealthy concentrations of air pollution, leading to increased morbidity and mortality primarily due to cardiovascular and respiratory causes (1).

Vulnerable groups include patients with chronic obstructive pulmonary disease (COPD), which is currently the fourth leading cause of death worldwide (2). Total deaths from COPD are predicted to increase by more than 30% in the next ten years and economic costs for the management of COPD are estimated at \$36 billion annually in the United States (3). Although smoking is the most important cause of COPD, a substantial proportion of cases cannot be explained by this lifestyle factor alone (4).

Exacerbations of COPD are a common cause of adult emergency hospital admissions and are associated with increased mortality and decreased quality of life. Patients may experience at least one exacerbation per year, (5) and as the disease worsens, exacerbations become more frequent and severe (6). The effect of environmental exposure on COPD exacerbations is not clear. A number of variables may trigger COPD exacerbations (7), and understanding and addressing the effects of air quality may be key in managing COPD exacerbations. From a policy perspective, detecting air pollution-induced health effects early can lead to more effective control of exposures and more appropriate interventions.

The present review evaluates the strength and consistency of current literature documenting the effect of different air pollutants on hospital admissions for COPD exacerbations. Previous meta-analytic studies on the effects of air pollution on COPD-related hospital admissions and mortality have focused on the effects of particles (8–11) or the effects of gases such as ozone and nitrogen

dioxide (12,13). This review is unique in that it simultaneously assesses the effects of key atmospheric pollutants, including gases and particulate matter, on hospital admissions for patients with an established diagnosis of COPD from a large number of studies globally.

## **Methods**

### **Objective**

To assess the effects of air pollutants on COPD hospital admissions by reviewing the literature from time-series and case-crossover studies.

### **Search strategy**

Two conceptual terms were developed for the search strategy: “*Environmental factors*” and “*health outcomes*” relating to COPD. Search terms were developed using combinations of controlled vocabulary and free-text terms. Only papers with title, keywords or abstracts including records from the search categories were included. Search terms from these categories were combined using the AND Boolean logic operator. “Environmental factors” refers to air pollution, including gases and particles suspected of affecting human health such as carbon monoxide (CO), nitrogen dioxide (NO<sub>2</sub>), sulphur dioxide (SO<sub>2</sub>), ozone (O<sub>3</sub>), and particulates with a diameter of less than 10 and 2.5 micrometres in diameter (PM<sub>10</sub> and PM<sub>2.5</sub> respectively). The primary “health outcome” of interest in this review is *COPD exacerbation* qualified by hospital admissions.

Searches were conducted through MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, BIOSIS & Science Citation Index from 1980 until September 2015 using PRISMA and MOOSE guidelines (14). We accessed the grey literature to address potential publication bias and searched additional sources including reports from the World Health

Organisation (WHO), the Committee on the Medical Effects of Air Pollution (COMEAP), and the Air Pollution Epidemiology Database (APED) from St George's University. The search strategy is included in the supplementary materials (SM).

### **Inclusion and exclusion criteria**

Based on the above, inclusion and exclusion criteria (Table 1) were applied to titles, keywords and abstracts, before obtaining full reports on the studies that appeared to meet the criteria.

### **Classification and quality assurance**

Two authors independently reviewed titles and abstracts for relevance and assessed whether they were related to the scope of this study. Relevant papers were included for full text review, and tested against the inclusion/exclusion criteria. The methodological quality of the studies was assessed based on population size, study duration and design, air pollutant exposure measurement, diagnosis of COPD, potential confounding factors, controls used, statistical methods, and length of follow up. A descriptive summary of the studies is included in Table 2 (SM).

### **Risk of bias assessment**

A risk of bias assessment was devised based upon the Newcastle-Ottawa scale (15) and assessment domains included the representativeness of exposure, ascertainment of exposure, comparability i.e. controlling for confounders, and reporting of missing data (Figure 8).

Small study bias was assessed using the "trim and fill" method (16) (Figure 9 SM). The percentage of variation between studies due to heterogeneity was assessed with Galbraith (radial) plots (Figure 10 SM) and quantified with Cochran's Q measure in random effects models. The  $I^2$

statistic was calculated as the weighted sum of squared differences between individual study effects and the pooled effect across studies as follows:

$$I^2 = 100\% \times (Q\text{-degrees of freedom})/Q.$$

### **Data extraction and synthesis of evidence**

Full text relevant studies were coded accordingly to address the topic focus of the review: study type (e.g. primary research, meta-analysis), focus of the study (e.g. health outcomes), country in which the research was conducted, duration of the study, and methodology employed (e.g. epidemiological study). Estimates of effects extracted from included studies were presented as odds ratios (OR), relative risks (RR) or percentage change (PC) in COPD hospital admissions. (See supplementary material for details).

## **Results**

### **Methodological classification of studies**

Among the 46 studies included in the meta-analysis, 15 were performed in North America and 19 in Europe. Eight studies were conducted in Asia, while limited information was available from South America and Australia. Therefore, three geographical clusters were defined based on available evidence from the literature.

Two methodological approaches were identified: time-series and case-crossover studies. The most common approach was ecological time-series investigations, where aggregated health outcomes of the total population were associated with daily variations in air pollutants after controlling for confounding factors, such as temperature or influenza epidemics. That approach has the potential for including a large number of days over several years for a large population



with advantages of improving the precision of estimate of effect of the exposure-response relationships. The vast majority of these studies analysed exposure-response relationships at single city level, with only six time-series multicity investigations (17–22).

Case-crossover studies measured COPD exacerbations in cohorts of COPD patients. Conceptually, case-crossover design is different from time-series as the unit of assessment is at the individual level, where each patient acts as their own control accounting for variation at the individual level. A total of 11 studies with a case-crossover design were included in the meta-analysis. The study population in those studies was relatively small compared with the time-series investigations, which would result in a smaller precision of the estimate. Only one case crossover study (23) was organised as a multicity study in 36 cities.

Air pollution exposure in all time-series and case-crossover studies used measurements from the nearest fixed air quality monitoring station. The number of fixed monitoring stations employed in each study was not always reported; but ranged from a single monitoring station up to 31 (24). The time-resolution of the measurements was most often 24-hour average values for meteorological parameters and particles, and 1-hour to 8-hour maximum levels for gaseous pollutants.

### **Meta-analysis of studies using single-pollutant models**

Figures 2 to 7 show forest plots for the converted odds ratios of COPD hospital admissions for PM<sub>10</sub>, PM<sub>2.5</sub>, CO, SO<sub>2</sub>, NO<sub>2</sub> and O<sub>3</sub> from single pollutant models.

## Effect of PM<sub>10</sub>

The pooled estimates of a total of 31 studies included in the meta-analysis for PM<sub>10</sub> showed a marginal effect of a 10 µg/m<sup>3</sup> increase of PM<sub>10</sub> on COPD hospital admissions (Figure 2) with very high heterogeneity ( $I^2=79.4\%$ ) between studies. Out of these, 23 were ecological time series, while the rest were organised as case-crossover investigations. While 28 estimated a positive association between COPD-related hospital admissions and PM<sub>10</sub> exposure, only 15 found that the association was significant.

Most of the studies were conducted in Europe and North America, where a marginal effect was estimated (OR: 1.01, 95%CI: 1.00-1.01 for Europe and 1.00, 95% CI: 1.00–1.01 for America respectively), while a stronger effect was reported for studies conducted in Asia (OR: 1.02, 95%CI: 1.01-1.03). The stronger effect reported in Asian studies might be explained by the approximately three-fold higher mean pollution levels of  $99.8\ \mu\text{g}/\text{m}^3 \pm 48.4$  compared with  $30.7\ \mu\text{g}/\text{m}^3 \pm 2.6$  and  $31.1\ \mu\text{g}/\text{m}^3 \pm 3.0$  for North America and Europe respectively, which were lower than the annual mean WHO guideline values. The meta-regression model also indicates a non-linear relationship with stronger effects reported at higher ambient concentrations (Figure 11 SM). The heterogeneity among European studies ( $I^2= 1.93\%$ ) was significantly lower than in the other two subgroups. The “trim and fill” method identified evidence of small-study bias on the effect estimates of PM<sub>10</sub>. Contrary to single-city studies, three multicity studies, one in Europe (25) and two in North America (20,21) did not find a significant association, while a case-crossover (23) and a time-series (22) study in ten US cities found a marginal association between PM<sub>10</sub> and COPD hospital admissions.

There is insufficient evidence to assess the lagged effects of particle exposure on COPD morbidity, as most studies did not specify the temporal lags of the dependent variables in the

regression. A further limitation includes the low temporal resolution of collected PM<sub>10</sub> data, which was in most studies the daily average.

### **Effect of PM<sub>2.5</sub>**

Due to the lack of available outdoor measurements for PM<sub>2.5</sub> or smaller particles, evidence available on their potential association with COPD morbidity is limited and the heterogeneity of the pooled meta-analysis was high ( $I^2 = 89.9\%$ ). Out of the 12 studies included in the meta-analysis (Figure 3), ten studies found a positive association; however only four found that the association was significant. Studies that collected measurements for both PM<sub>2.5</sub> and PM<sub>10</sub> fractions found similar associations between COPD hospital admissions and these fractions (21,22,26–31), but overall a stronger association was found with PM<sub>2.5</sub> (OR: 1.03, 95%CI: 1.01-1.05) compared with PM<sub>10</sub>, which might be explained by the fact that smaller particles may penetrate deeper into the lungs.

Similarly with PM<sub>10</sub>, the majority of studies were performed as time-series investigations, and most of the evidence comes from North America. When the effect estimates in the European and North American results were pooled, the heterogeneity was significantly reduced ( $I^2 < 50\%$ ). The effect of PM<sub>2.5</sub> was stronger in Asia (OR: 1.04, 95% CI: 1.00-1.08) but there was large heterogeneity. Highest concentration levels of PM<sub>2.5</sub> of  $41.2 \mu\text{g}/\text{m}^3 \pm 2.7$ , were reported in Asia (where the effect was stronger and significant), twice as high as in Europe ( $23.4 \mu\text{g}/\text{m}^3 \pm 5.3$ ) and four times higher than in North America ( $11.3 \mu\text{g}/\text{m}^3 \pm 3.3$ ), where the effects were lower and non-significant and levels were below annual mean WHO guideline values. The meta-regression model also pointed towards a non-linear relationship between COPD hospital admissions and ambient pollution levels, as there was a higher effect at higher concentrations (Figure 12 SM).

Although there appears to be a relationship between PM<sub>2.5</sub> and COPD hospital admissions, results should be interpreted with caution due to the limited number of included studies. The “trim and fill” method did not detect any small-city bias. Two studies were organised as multicity investigations, one in 202 US cities (18) and one in seven Canadian cities (21), and reported a non-significant association between PM<sub>2.5</sub> exposure and COPD exacerbations.

As in the case of PM<sub>10</sub>, limited information exists on seasonal effects of fine particles on health outcomes with only one study in a tropical climate estimating larger effects in the cool season (32). Limited evidence is available on the lagged effects of PM<sub>2.5</sub> exposure on COPD morbidity and points towards a shorter temporal lag than PM<sub>10</sub> of up to two days (30).

### **Effect of CO**

Pooled results of 15 studies for CO (Figure 4) showed a small but significant effect of a 1 mg/m<sup>3</sup> increase in CO on COPD admissions (OR: 1.02, 95% CI: 1.01-1.03) with moderate heterogeneity ( $I^2 = 50.73\%$ ) between studies. We excluded one study in Asia from the pooled estimate (33) that increased the heterogeneity significantly ( $I^2=83.6\%$ ). The re-scaled ORs for this study were 1.67 (95% CI 1.37, 2.04) in the warm season and 2.70 (95% CI 2.04, 3.58) in the cool season. Apart from two European case-crossover studies (21,30) that found a strong positive association, all included studies were time-series investigations. There was some evidence of small-study bias in the trim and fill funnel plot, supported by the non-significant negative association estimated by the only multicity investigation from seven Canadian cities (21).

There is insufficient evidence on the association between COPD hospital admissions and CO exposure in geographical locations other than Europe (6 studies) and North America (7 studies). The heterogeneity between studies was significantly reduced in both these geographical

subgroups. Studies in Europe estimated overall stronger association of OR: 1.04 (95% CI: 1.02-1.06) ( $I^2 = 47.3\%$ ) than in North America OR: 1.02 (1.01–1.03) ( $I^2 = 37.5\%$ ), possibly because CO concentrations in Europe were higher ( $2.1 \text{ mg/m}^3 \pm 0.7$ ) compared with North America ( $1.5 \text{ mg/m}^3 \pm 0.2$ ) and the meta-regression indicated that there is a non-linear association between effect and ambient concentrations (Figure 13 SM).

Most studies found significant associations with acute (25,34) or lagged effects of up to three days (21,30,31,35).

### **Effect of SO<sub>2</sub>**

The overall pooled estimate of SO<sub>2</sub> exposure indicated a borderline effect with COPD admissions with moderate heterogeneity between studies ( $I^2 = 50.8\%$ ). Out of the 23 studies included in the meta-analysis, 18 employed a time-series methodology. There was evidence of small-study bias (Figure 9).

Most of the studies were performed in Europe with small heterogeneity ( $I^2 = 6.72\%$ ) between studies. The effects were clustered in geographical locations with a stronger positive effect estimate in Asia (OR: 1.03, 95% CI: 1.00-1.06) compared with the effects in North America, where studies failed to detect a significant association, and only a borderline effect in Europe. SO<sub>2</sub> levels in North America and Europe were similar with small SE ( $18.1 \text{ } \mu\text{g/m}^3 \pm 4.7$  and  $18.0 \text{ } \mu\text{g/m}^3 \pm 3.2$ ) while levels in Asia were higher with large SE ( $25.1 \text{ } \mu\text{g/m}^3 \pm 11.30$ ). The meta-regression model approximated a linear relationship between effect size and pollution levels (Figure 14 SM).

Apart from the spatial variation of the effect of SO<sub>2</sub>, a seasonal effect might also underpin the estimated association. Two studies in a tropical climate in Taiwan (33,36) found a significant association between SO<sub>2</sub> and COPD hospital admissions only in the cool season (Temp <25°C). A

possible explanation might be increased coal burning for heating during the cool season in developing countries where levels were higher. However seasonal differences were estimated in a five year European study (37) with a very small but insignificant association observed in winter but no relationship in the summer. Most studies estimated acute effects for SO<sub>2</sub> (21,34) or two-day lagged effects (21,30,38). Only one study (35) estimated longer lagged effects of up to 13 days.

## **Effect of NO<sub>2</sub>**

Results for NO<sub>2</sub> (Figure 6) showed an association (OR: 1.03, 95% CI: 1.02-1.05) between a 10µg/m<sup>3</sup> increase in NO<sub>2</sub> and COPD admissions with high heterogeneity ( $I^2=91.5\%$ ). We found evidence of small-study bias in single-city studies (Figure 9). A positive association was reported in 25 out of 27 studies, and a significant one in 11 studies. Only one multicity study in North America (21) and one in Europe (39) reported a negative non-significant effect.

The majority of evidence comes from Europe, where the heterogeneity between studies was moderate ( $I^2=55\%$ ). The estimated effects in Europe and North America were similar (OR: 1.01, 95% CI: 1.00-1.02), but lower than the effects in Asia, where the confidence intervals were wider (OR: 1.07, 95%CI: 1.01-1.13). Highest NO<sub>2</sub> levels were measured in Europe (57.9 µg/m<sup>3</sup> ± 8) and Asia (51.2 µg/m<sup>3</sup> ± 2.4) and lowest levels in North America (42.7 µg/m<sup>3</sup> ± 10.8), but in all geographical clusters were above mean annual WHO guideline values. A non-linear relationship between mean levels and effect estimates was estimated in the meta-regression with stronger effects at higher concentrations (Figure 15 SM).

The findings on lagged effects of NO<sub>2</sub> exposure are inconsistent. Three studies found significant acute effects of same day NO<sub>2</sub> exposure with COPD exacerbations (25,40,41) or one to two day lagged effects (33,42). Longer three-day lag effects were reported in three large studies

(21,27,35), while four smaller studies reported longer lagged effects lasting of up to eight days (30,39,43,44).

### **Effect of O<sub>3</sub>**

In total, there were 23 studies investigating the effect of O<sub>3</sub> on COPD hospital admissions, nine were performed in North America, nine in Europe, three in Asia and one in Australia (Figure 7). As in the case of NO<sub>2</sub>, the heterogeneity between studies was large ( $I^2 = 87.23\%$ ). Of the 22 studies, 18 reported a positive effect; however it was significant only in ten studies. Overall, the pooled estimates showed that there was a small positive effect of O<sub>3</sub> on COPD hospital admissions (OR: 1.02, 95% CI: 1.01–1.03). Mean levels of O<sub>3</sub> were similar in all geographical locations ranging from 43.9 µg/m<sup>3</sup> in Asia to 53.6 µg/m<sup>3</sup> in North-America and the meta-regression model estimated a linear relationship with the effects (Figure 16 SM).

The heterogeneity between studies in geographical subgroups remained high. The pooled models showed that the strongest effect (OR: 1.04, 95% CI: 1.03-1.05) was estimated for Asian countries, while the effects were marginally significant for North America (OR: 1.01, 95% CI: 1.00-1.02), and insignificant for Europe (OR: 1.01, 95% CI: 0.99-1.04). Contrary to the pooled models, the multicity studies found an insignificant effect in North America (21,23) and a significant positive effect in Europe (17). There was no evidence of small-study bias.

The effect of seasonality on the association between O<sub>3</sub> and COPD-related hospital admissions is unclear. One study in Canada (21) estimated that the effect was nearly twice as large during the warm season as over the whole year. Contrary, a study in a tropical climate (33) estimated that the effect was twice as large in the cool season.

## **Risk of bias assessment**

The risk of bias (and the proportion of which had low, unclear or high risk) for the studies included in this review are shown in Figure 8. Detailed descriptions for each individual study are included in the supplementary materials.

## **Discussion**

To our knowledge this is the first study to use meta-analytic techniques to pool the effect estimates of the associations between COPD admissions with gaseous pollutants (NO<sub>2</sub>, O<sub>3</sub>, CO and SO<sub>2</sub>) and particulate matter simultaneously. The models showed suggestive evidence that all investigated pollutants may have a small but significant effect on COPD hospital admissions. These findings however, come from a relative small number of studies with high heterogeneity between them. Geographical clustering of the effects of pollution on COPD hospital admissions was evident and reduced heterogeneity significantly.

## **Particulate Matter**

Previous systematic meta-analyses have focused on the association between COPD exacerbations (8,9) with exposure to particulate matter. Zhu and colleagues (11) estimated a 2.7% increase for COPD hospital admissions (95% CI: 1.9%-3.6%) for every 10 µg/m<sup>3</sup> increase in PM<sub>10</sub>, and reported large heterogeneity in effect estimates from  $I^2 = 83.9%$  (11) to 79.4% (9). We found a marginally significant effect estimate for PM<sub>10</sub> (1.01, 95% CI: 1.0-1.02) similar to Song et al (9) but smaller than Zhu and colleagues (11). Song and colleagues (9) found that the strength of the association of COPD hospital admissions with PM<sub>10</sub> varied among geographical locations with an effect of 1% in China and Europe but a larger effect of 2% in the United States. We estimated a similar effect of 1% in Europe with very little heterogeneity ( $I^2=1.93%$ ); however a



smaller effect of 1% in North America, and a larger effect in Asia of 3% (95% CI: 2% to 5%). A possible explanation might be that unlike both previous meta-analyses (9,11), we did not include studies where asthma was not separated in the diagnosis. Moreover, we found evidence of a non-linear relationship where higher effects were reported at higher concentrations.

Only one meta-analysis (45) estimated the association of COPD admissions (excluding asthma) with PM<sub>2.5</sub> exposure and found a similar association 1.02 (95% CI: 1.01-3.71) to this study (OR: 1.03, 95% CI: 1.01-1.05). In line with the findings of Atkinson and colleagues (45), we found large heterogeneity between studies but no evidence of small-study bias in the effect estimates of PM<sub>2.5</sub> for COPD hospital admissions.

It is possible that the marginal effect of particulate matter estimated in this and previous meta-analytic studies might be influenced by small-study bias. Large multicity studies in North America and Europe (19–21) failed to detect a significant association between outdoor PM<sub>10</sub> levels and COPD hospital admissions. Similarly, the two multicity studies in North America (18,21) did not find a significant association between PM<sub>2.5</sub> exposure and COPD hospital admissions.

The effect of seasonal variation on the association between PM<sub>10</sub> exposure and COPD exacerbations is not clear. One multicity study in Italy (19) reported that the association is 7.5 times stronger in the summer season. A study in Taiwan however (33), found a stronger effect in the cool season. A potential explanation for the observed differences might be related to behavioural patterns of the population regarding time spent outdoors, which may vary in different climates. Another possible explanation in the Asian study may be related to the extensive use of mechanical cooling and air filtration in the tropical climate during the warm season that may reduce exposure to PM. Similar results have been reported by Janssen et al (46) in the re-analysis

of the National Morbidity Mortality Air Pollution study (NMMAPS) in 14 US states, where the percentage of households with air handling units had a significant modification effect on COPD hospital admissions.

### **Gaseous pollutants**

The systematic evaluation of the association between COPD exacerbations with gaseous pollutants indicates a potential link between CO and SO<sub>2</sub> levels with moderate heterogeneity and strong geographical clustering. Both pollutants appeared in most studies to have acute effects or short lagged effects of up to three and two days respectively on COPD admissions, and a stronger effect in the winter season. Marginally stronger effects of CO were estimated in Europe than North America. A potential explanation for the difference in effects estimated between Europe and North America may be related to different levels of ambient CO concentrations, or the methodological design of studies, such as the absence of multi-city investigations in Europe.

The effect estimates of SO<sub>2</sub> in each geographical subgroup indicated that the association was only significant in Asian countries with stronger effect in the winter season, marginally significant in Europe, and insignificant in North America where the majority evidence comes from, possibly because SO<sub>2</sub> remains a predominant pollutant in developing countries. The only two available multi-city studies on the effects of SO<sub>2</sub> found contradictive results; one study in Europe reporting a marginal positive association (17) and one study in North America (21) reported a negative non-significant association. A possible explanation is that the chronological difference between these two studies reflects differences in outdoor SO<sub>2</sub> concentrations.

The associations between NO<sub>2</sub> and O<sub>3</sub> exposure with COPD hospital admissions is less well understood, as the heterogeneity between studies in this review was large. Both pollutants showed

marginal associations in Europe and North America, and stronger effects in Asia. Only three studies in Asia found an association both with O<sub>3</sub> and NO<sub>2</sub> (29,33,40). Studies in Europe and North America found an association either with NO<sub>2</sub> (24,30,35,43) or O<sub>3</sub> alone (17,27,39,47,48).

## **Limitations**

A number of limitations in the methodological design of the studies included in this review do not allow establishing a clear link between the effects of environmental pollution on COPD exacerbations. Using hospital admissions as an indication of exacerbation is a potential source of ecological fallacy, as it ignores individual-level characteristics and assesses health outcomes at group level. Relationships at individual level might not reflect group level relationships and vice versa. Health-care use in COPD can vary depending on access, and it was not always possible to separate emergency from scheduled admissions, adding further uncertainty to the estimation of exacerbations.

Although many studies employed both single-pollutant and multi-pollutant models, results were included only from single-pollutant models and the findings do not account for any covariance between air pollutants (such as NO<sub>2</sub> and O<sub>3</sub> or NO<sub>2</sub> and PM). Other unmeasured pollutants in the mixture might also be important in the observed health outcomes (such as ultrafine particles). The confounding effects of temperature and humidity add further challenges. Although we know that there are seasonal effects on COPD exacerbations in northern and southern regions (49), the relationships between temperature and humidity with COPD admissions is not clear.

The studies were grouped based in geographical location, which had the potential of reducing the heterogeneity of the subgroups, however the small sample size limited the interpretation of the results. We used random-effects models, which can account for the heterogeneity between studies better than fixed models. While this standardised method may reduce the small-study bias, it cannot differentiate multi-city from single-city studies if the standard error is similar. Moreover, while the RE pooled models assume a linear relationship between air pollutants and effect estimates, we found evidence of a non-linear relationship with higher effects reported at higher concentrations for all pollutants apart from O<sub>3</sub> and SO<sub>2</sub> that exhibited a linear relationship.

A significant limitation of the studies included the low spatio-temporal resolution of air pollution measurements from fixed monitoring stations as a surrogate for personal exposure. However, in practise air quality is highly granular and people, particularly those with chronic respiratory diseases, may spend a large fraction of their time indoors, where they might be exposed to a mixture of emissions from indoor sources. Missing daily monitoring data add further uncertainty in the analysis of time-series studies with daily lags in the exposure variable. Rather than using fixed site monitors as a proxy for “true” exposures, the development of hybrid models that combine pollutant dispersion models with space-time-activity models may prove to be a more effective way of examining the effects of personal environmental exposure on health (50).

## **Conclusions**

A key finding of this review is that the effects of separate pollutants on COPD admissions appears to vary across geographical regions. Effects were evident even at concentration below current guideline values indicating the need to lower thresholds to protect such vulnerable groups.

## **Competing Interests**

JKQ reports grants from the Medical Research Council (MRC), GlaxoSmithKline (GSK), British Lung Foundation (BLF), Wellcome Trust, during the conduct of the study, and personal fees from AstraZeneca outside of the submitted work. LS reports grants from the Wellcome Trust, MRC, and National Institute for Health Research (NIHR) during the conduct of the study, and personal fees from GSK outside of the submitted work. All authors report no other conflicts of interest.

## **Author Contributions**

EM and LC carried out the background research, literature search, screening of articles, data extraction, data interpretation, produced the figures and the first draft. MOK assisted with screening and data extraction. JKQ conceived the study, made critical revisions of the manuscript for intellectual content and supported completion of the first draft. BB provided oversight for the study, commented on subsequent drafts of the manuscript and approved the final version. RLJ and FJK commented on the first draft and gave advice on data interpretation and analysis. All other authors commented on subsequent drafts and approved the final version.

## **Acknowledgements**

The research was supported by the Medical Research Council-Public Health England (MRC-PHE) Centre for Environment and Health and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

## References

1. Kelly FJ, Fussell JC. Air pollution and airway disease. *Clin Exp Allergy* 2011;41(8):1059–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21623970>
2. World Health Organisation. World Health Statistics 2008 [Internet]. Theakston F, editor. World Health Organisation. Geneva: World Health Organisation; 2008. 112 p. Available from: [http://www.who.int/whosis/whostat/EN\\_WHS08\\_TOCintro.pdf](http://www.who.int/whosis/whostat/EN_WHS08_TOCintro.pdf)
3. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged  $\geq 18$  years in the United States for 2010 and projections through 2020. *Chest* 2015;147(1):31–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25058738>
4. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010;182(5):693–718.
5. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax*. 2002;57(10):847–52.
6. Hurst JR, Jørgen V, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, Calverley P, Rennard S, Wouters EFM, Wedzicha JA. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 2010;363(12):1128–38.
7. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. *Lancet* [Internet]. Elsevier Ltd; 2007;370(9589):786–96. Available from: [http://dx.doi.org/10.1016/S0140-6736\(07\)61382-8](http://dx.doi.org/10.1016/S0140-6736(07)61382-8)
8. Atkinson RW, Mills IC, Walton HA, Anderson HR. Fine particle components and health — a systematic review and meta-analysis of epidemiological time series studies of daily mortality and hospital admissions. *J Expo Sci Environ Epidemiol* [Internet]. Nature Publishing Group; 2015;25(2):208–14. Available from: <http://dx.doi.org/10.1038/jes.2014.63>
9. Song Q, Christiani D, Xiaorong Wang E, Ren J. The Global Contribution of Outdoor Air Pollution to the Incidence, Prevalence, Mortality and Hospital Admission for Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* [Internet]. 2014;11:11822–32. Available from: <http://www.mdpi.com/1660-4601/11/11/11822/>
10. Sunyer J, Schwartz J, Tobías A, Macfarlane D, Garcia J, Antó JM. Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis. *Am J Epidemiol*. 2000;151(1):50–6.
11. Zhu R, Chen Y, Wu S, Deng F, Liu Y, Yao W. The relationship between particulate matter (PM10) and hospitalizations and mortality of chronic obstructive pulmonary disease: A meta-analysis. *COPD J Chronic Obstr Pulm Dis* [Internet]. 2013;10(3):307–15. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2013348801>
12. Atkinson R, Mills IC, Walton H, Kang S, Anderson HR. Systematic review and quantitative meta-analysis of the evidence for associations between chronic and short-term exposure to outdoor air pollutants and health. Department of Health Policy Research Project. 2014.

13. Mills IC, Atkinson RW, Kang S, Walton H, Anderson HR. Quantitative systematic review of the associations between short-term exposure to nitrogen dioxide and mortality and hospital admissions. *BMJ Open* [Internet]. 2015;5(5):e006946 doi:10.1136/bmjopen – 2014–006946. Available from: doi:10.1136/bmjopen-2014-006946
14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of Observational Studies. *JAMA*. 2008;283(15):2008–12.
15. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M TP. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*. [Internet]. 2015 [cited 2015 Dec 10]. Available from: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
16. Duval S, Tweedie R. A Nonparametric “ Trim and Fill ” Method of Accounting for Publication Bias in Meta-Analysis. *J Am Stat Assoc*. 2000;95(449):89–98.
17. Anderson HR, Spix C, Medina S, Schouten JP, Castellaque J, Rossi G, Zmirou D,. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. *Eur Respir J* [Internet]. 1997 May 1 [cited 2014 Nov 24];10(5):1064–71. Available from: <http://erj.ersjournals.com/content/10/5/1064>
18. Dominici F, Peng RD, Bell ML, Pham L, McDermott A, Zeger SL, Samet JM. Fine Particulate Air Pollution and Hospital Admission for Cardiovascular and Respiratory Diseases. *JAMA*. 2006;295(10):1127–34.
19. Faustini A, Stafoggia M, Colais P, Berti G, Bisanti L, Cadum E, Cernigliaro A, Mallone S, Scarnato C, Forastiere F. Air pollution and multiple acute respiratory outcomes. *Eur Respir J*. 2013;42(2):304–13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23314899>
20. Schwartz, J; Zanobetti, A; Bateson T. Special report: Revised analyses of time-series studies of air pollution and health. Health Effects Institute. 2003.
21. Stieb DM, Szyszkowicz M, Rowe BH, Leech JA. Air pollution and emergency department visits for cardiac and respiratory conditions: a multi-city time-series analysis. *Environ Health*. 2009 Jan;8(2):25. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2703622&tool=pmcentrez&rendertype=abstract>
22. Zanobetti A, Schwartz J, Dockery DW. Airborne Particles Are a Risk Factor for Hospital Admissions for Heart and Lung Disease. *Environ Health Perspect*. 2000 Nov;108(11):1071–7. Available from: <http://www.jstor.org/stable/3434961?origin=crossref>
23. Medina-Ramón M, Zanobetti A, Schwartz J. The effect of ozone and PM10 on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study. *Am J Epidemiol*. 2006 Mar 15 [cited 2015 Jan 9];163(6):579–88. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16443803>
24. Yang Q, Chen Y, Krewski D, Burnett RT, Shi Y, McGrail KM. Effect of short-term exposure to low levels of gaseous pollutants on chronic obstructive pulmonary disease hospitalizations. *Env Res*. 2005;99(1):99–105. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16053934>
25. Lagravinese R, Moscone F, Tosetti E, Lee H. The impact of air pollution on Hospital admissions: evidence

from Italy. *Reg Sci Urban Econ*. Elsevier B.V.; 2014;49:278–85. Available from: <http://ideas.repec.org/p/rtr/wpaper/0170.html>

26. Belleudi V, Faustini A, Stafoggia M, Cattani G, Marconi A, Perucci CA, Forastiere F. Impact of fine and ultrafine particles on emergency hospital admissions for cardiac and respiratory diseases. *Epidemiology*. 2010;21(3):414–23. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed9&AN=2010226019>
27. Burnett RT, Smith-Doiron M, Stieb D, Cakmak S, Brook JR. Effects of Particulate and Gaseous Air Pollution on Cardiorespiratory Hospitalizations. *Arch Environ Health*. 1999;54(2):130–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10094292>
28. Chen Y, Yang Q, Krewski D, Shi Y, Burnett RT, McGrail K. Influence of Relatively Low Level of Particulate Air Pollution on Hospitalization for COPD in Elderly People. *Inhal Toxicol*. 2004;16(1):21–5. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed6&AN=2004037791>
29. Ko FS, Tam W, Wong T, Chan DPS, Tung AH, Lai CKW, Hui DS. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. *Thorax*. 2007;62(9):780–5. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2117326&tool=pmcentrez&rendertype=abstract>
30. Santus P, Russo A, Madonini E, Allegra L, Blasi F, Centanni S, Miadonna A, Schiraldi G, Amaducci S. How air pollution influences clinical management of respiratory diseases. A case-crossover study in Milan. *Respir Res*. 2012;13(95).
31. Slaughter JC, Kim E, Sheppard L, Sullivan JH, Larson T V, Claiborn C. Association between particulate matter and emergency room visits, hospital admissions and mortality in Spokane, Washington. *J Expo Anal Environ Epidemiol* [Internet]. 2005;15(2):153–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15187986>
32. Tsai SS, Chiu HF, Liou SH, Yang CY. Short-term effects of fine particulate air pollution on hospital admissions for respiratory diseases: a case-crossover study in a tropical city. *J Toxicol Environ Heal Part A*. 2014;77(18):1091–101. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=25072896>
33. Lee IM, Tsai SS, Chang CC, Ho CK, Yang CY. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a tropical city: Kaohsiung, Taiwan. *Inhal Toxicol*. 2007;19(5):393–8. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17365044>
34. Fusco D, Forastiere F, Michelozzi P, Spadea T, Ostro B, Arca M, Perucci CA. Air pollution and hospital admissions for respiratory conditions in Rome, Italy. *Eur Respir J*. 2001;17(6):1143–50. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11491157>
35. Peel JL, Tolbert PE, Klein M, Metzger KB, Flanders WD, Todd K, Mulholland JA, Ryan PB, Frumkin H. Ambient Air Pollution and Respiratory Emergency Department Visits. *Epidemiology*. 2005;16(2):164–74. Available from: <http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00001648-200503000-00004>



36. Yang C-Y, Chen C-J. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a subtropical city: Taipei, Taiwan. *J Toxicol Environ Health A*. 2007;70(14):1214–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17573635>
37. Sunyer J, Saez M, Murillo C, Castellsague J, Martinez F, Anto JM. Air Pollution and Emergency Room Admissions for Chronic Obstructive Pulmonary Disease: A 5-year Study. *Am J Epidemiol*. 1993;137(7):701–5.
38. Arbex MA, De Souza Conceicao GM, Cendon SP, Arbex FF, Lopes AC, Moyses EP, Santiago SL, Saldiva PH, Pereira LA, Braga AL. Urban air pollution and chronic obstructive pulmonary disease-related emergency department visits. *J Epidemiol Community Heal*. 2009;63:777–83. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed9&AN=2009512514>
39. Tenias J M, Ballester F, Perez-Hoyos S RM. Air pollution and hospital emergency room admissions for chronic obstructive pulmonary disease in Valencia, Spain. *Arch Environ Health*. 2002;57:41–7.
40. Qiu H, Yu ITS, Wang X, Tian L, Tse LA, Wong TW. Season and humidity dependence of the effects of air pollution on COPD hospitalizations in Hong Kong. *Atmos Environ*. Elsevier Ltd; 2013 Sep [cited 2015 Jan 8];76:74–80. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S135223101200698X>
41. Morgan G, Corbett S, Wlodarczyk J. Air pollution and hospital admissions in Sydney, Australia, 1990 to 1994. *Am J Public Health*. 1998;88(12):1761–6. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed4&AN=1999014022>
42. Cirera L, Garcia-Marcos L, Gimenez J, Moreno-Grau S, Tobias A, Perez-Fernandez V, Elvira-Rendeles B, Guillen JJ, Navarro C. Daily effects of air pollutants and pollen types on asthma and COPD hospital emergency visits in the industrial and Mediterranean Spanish city of Cartagena. *Allergol Immunopathol (Madr)*. 2012;40(4):231–7. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed10&AN=2012407566>
43. Sauerzapf V, Jones a P, Cross J. Environmental factors and hospitalisation for chronic obstructive pulmonary disease in a rural county of England. *J Epidemiol Community Health*. 2009;63(4):324–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19208692>
44. Peacock JL, Anderson HR, Bremner S a, Marston L, Seemungal T a, Strachan DP, Wedzicha JA. Outdoor air pollution and respiratory health in patients with COPD. *Thorax*. 2011 Jul;66(7):591–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21459856>
45. Atkinson RW, Kang S, Anderson HR, Mills IC, Walton HA. Epidemiological time series studies of PM2.5 and daily mortality and hospital admissions: a systematic review and meta-analysis. *Thorax*. 2014;69(7):660–5. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4078677&tool=pmcentrez&rendertype=abstract>
46. Janssen NAH, Schwartz J, Zanobetti A, Suh HH. Air conditioning and source-specific particles as modifiers of the effect of PM10 on hospital admissions for heart and lung disease. *Environ Health Perspect*. 2002;110(1):43–9.
47. Desqueyroux H, Pujet JC, Prosper M, Le Moullec Y, Momas I. Effects of air pollution on adults with chronic

obstructive pulmonary disease. *Arch Environ Health*. 2002;57(6):554–60. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12696653>

48. Tolbert PE, Klein M, Metzger KB, Peel J, Flanders WD, Todd K, Mulholland JA, Ryan PB, Frumkin H. Interim results of the study of particulates and health in Atlanta (SOPHIA). *J Expo Anal Environ Epidemiol*. 2000;10(5):446–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11051535>
49. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, Yates JC, Calverley PM. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. *Eur Respir J*. 2012;39:38–45.
50. Beevers SD, Kitwiroon N, Williams ML, Kelly FJ, Ross Anderson H, Carslaw DC. Air pollution dispersion models for human exposure predictions in London. *J Expo Sci Environ Epidemiol*. 2013;23(6):647–53. Available from: <http://dx.doi.org/10.1038/jes.2013.6>
51. Anderson HR, Bremner SA, Atkinson RW, Harrison RM, Walters S. Particulate matter and daily mortality and hospital admissions in the west midlands conurbation of the United Kingdom: associations with fine and coarse particles, black smoke and sulphate. *Occup Environ Med*. 2001;58(8):504–10.
52. Canova C, Dunster C, Kelly FJ, Minelli C, Shah PL, Caneja C, Tumilty MK, Burney P. PM10-induced hospital admissions for asthma and chronic obstructive pulmonary disease: the modifying effect of individual characteristics. *Epidemiology*. 2012;23(4):607–15. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22531667>
53. Cengiz MA, Terzi Y. Comparing models of the effect of air pollutants on hospital admissions and symptoms for chronic obstructive pulmonary disease. *Cent Eur J Public Health*. 2012;20(4):282–6.
54. Linn WS, Szlachcic Y, Henry G, Kinney PL, Berhane KT. Air pollution and daily hospital admissions in Metropolitan Los Angeles. *Environ Health Perspect*. 2000;108(5):427–34.
55. McGowan JA, Hider PN, Chacko E, Town GI. Particulate air pollution and hospital admissions in Christchurch, New Zealand. *Aust N Z J Public Health*. 2002;26(1):23–9.
56. Mehta AJ, Schindler C, Perez L, Probst-Hensch N, Schwartz J, Brandl O, Karrer W, Tschopp JM, Rochat T, Kunzli N. Acute respiratory health effects of urban air pollutants in adults with different patterns of underlying respiratory disease. *Swiss Med Wkly [Internet]*. 2012;142:w13681. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=23076649>
57. Meszaros D, Markos J, FitzGerald DG, Walters EH, Wood-Baker R. An observational study of PM10 and hospital admissions for acute exacerbations of chronic respiratory disease in Tasmania, Australia 1992-2002. *BMJ Open Respir Res [Internet]*. 2015; 2: e000063–e000063. Available from: <http://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2014-000063>
58. Milutinovic S, Nikic D, Stosic L, Stankovic A, Bogdanovic D. Short-term association between air pollution and emergency room admissions for chronic obstructive pulmonary disease in Nis, Serbia. *Cent Eur J Public Health. Central European Journal of Public Health*; 2009;17(1):8–13.
59. Ponka A, Virtanen M. Chronic bronchitis, emphysema, and low-level air pollution in Helsinki, 1987-1989. *Env Res*. 1994;65(2):207–17.

60. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. *Am J Respir Crit Care Med.* 1994;150(3):648–55.
61. Schwartz J. Air Pollution and Hospital Admissions for the Elderly in Birmingham, Alabama. *Am J Epidemiol.* 1994;139(6):589–98.
62. Shrestha SL. Time series modelling of respiratory hospital admissions and geometrically weighted distributed lag effects from ambient particulate air pollution within Kathmandu Valley, Nepal. *Environ Model Assess.* 2007;12(3):239–51.
63. Tao Y, Mi S, Zhou S, Wang S, Xie X. Air pollution and hospital admissions for respiratory diseases in Lanzhou, China. *Environ Pollut. Elsevier Ltd;* 2014;185:196–201.
64. Tian L, Ho K -f., Wang T, Qiu H, Pun VC, Chan CS, Louie PK, Yu IT. Ambient Carbon Monoxide and the Risk of Hospitalization Due to Chronic Obstructive Pulmonary Disease. *Am J Epidemiol.* 2014;180(12):1159–67.
65. Wordley J, Walters S, Ayres J. Short term variations in hospital admissions and mortality and particulate air pollution. *Occup Environ Med.* 1997;54:108–16.
66. Zanobetti A, Schwartz J, Gold D. Are There Sensitive Subgroups for the Effects of Airborne Particles ? *Environ Health Perspect.* 2000;108(9):841–5.
67. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA.* 1998;280(19):1690–1.
68. Higgins, JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* The Cochrane Collaboration; 2011. 7.7.7.2 [Internet]. [Accessed 2015 Sep 2]. Cochrane Collaboration; 2011. 7.7.7.2 Available from: <http://handbook.cochrane.org/>
69. *The Handbook of Research Synthesis and Meta-Analysis, Second Edition.* Cooper H, Hedges LV VJ, editor. Rusell Sage Foundation; 2009. 358 - 376 p.
70. R Core Team. R: A language and environment for statistical computing. [Internet]. 2014 [cited 2015 Dec 11]. Available from: <https://cran.r-project.org/doc/manuals/r-release/fullrefman.pdf>
71. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw* [Internet]. 2010;36(3):1–48. Available from: <https://www.jstatsoft.org/article/view/v036i03/v36i03.pdf>
72. World Health Organization. Ambient (outdoor) air quality and health: Fact sheet N°313 [Internet]. 2014 [cited 2016 May 9]. Available from: <http://www.who.int/mediacentre/factsheets/fs313/en/>

## Figures

**Figure 1:** Flow chart of the literature search and screening process.

**Figure 2:** Pollution levels and summary estimates (95% confidence intervals) for COPD related hospital admissions per 10  $\mu\text{g}/\text{m}^3$  increase in  $\text{PM}_{10}$ .

**Figure 3:** Pollution levels and summary estimates (95% confidence intervals) for COPD related hospital admissions per 10  $\mu\text{g}/\text{m}^3$  increase in  $\text{PM}_{2.5}$ .

**Figure 4:** Pollution levels and summary estimates (95% confidence intervals) for COPD related hospital admissions per 1  $\text{mg}/\text{m}^3$  increase in CO levels.

**Figure 5:** Pollution levels and summary estimates (95% confidence intervals) for COPD related hospital admissions per 10  $\mu\text{g}/\text{m}^3$  increase in  $\text{SO}_2$  levels.

**Figure 6:** Pollution levels and summary estimates (95% confidence intervals) for COPD hospital related admissions per 10  $\mu\text{g}/\text{m}^3$  increase in  $\text{NO}_2$  levels.

**Figure 7:** Pollution levels and summary estimates (95% confidence intervals) for COPD hospital related admissions per 10  $\mu\text{g}/\text{m}^3$  increase in  $\text{O}_3$  levels.

**Figure 8:** Risk of bias assessment for studies included in the meta-analysis.

Table 1: Inclusion and exclusion criteria

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> <li>• Reports a specific outcome of COPD exacerbation defined by hospital or emergency department admissions.</li> <li>• Recorded by clinician or in hospital records using the codes for the International Classification of Diseases Ninth and Tenth Revisions (ICD-9 490-496 excluding 493 for asthma; and ICD-10 J44.1-J44.9).</li> <li>• Reports a measure of air quality, either from a fixed monitoring station, indoor environment or personal exposure (indoor to be analysed separately from outdoor).</li> <li>• Reports the findings of a primary research study or secondary analysis.</li> <li>• Published in English</li> <li>• Reported results from single-pollutant models.</li> </ul>	<ul style="list-style-type: none"> <li>• Studies of the same author that repeat results (the most recent were selected).</li> <li>• Studies that included asthma (ICD-9 493) were excluded because of clinical and pathological differences between COPD and asthma (19).</li> <li>• Incorrect outcome: Included other respiratory diseases combined with COPD in the statistical analysis.</li> <li>• Uncertain diagnosis of COPD.</li> <li>• Did not report or provide calculable Odds Ratio (OR), Relative Risk (RR), or Percentage Change (PC) and 95% Confidence Intervals (CIs).</li> <li>• Poor quality: lacked adjustment for potential confounders, missing data, inadequate statistical analysis.</li> </ul>